Cite
HARVARD Citation
West, H. et al. (2022). Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. Journal for immunotherapy of cancer. 10 (2), p. . [Online].